AG
KALV

Advisor Group’s KalVista Pharmaceuticals KALV Stock Holding History

Advisor Group’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-50
Closed -$1K – 5292
2019
Q1 		$1K Hold
50
– – ﹤0.01% 5079
2018
Q4 		$1K Hold
50
– – ﹤0.01% 4974
2018
Q3 		$1K Sell
50
-50
-50% -$676 ﹤0.01% 4976
2018
Q2 		$1K Buy
+100
New +$883 ﹤0.01% 4805

Other funds holding KALV

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Advisor Group's KALV Position: Q2 2019 in Review

Advisor Group sold out of KalVista Pharmaceuticals (KALV) in Q2 2019, closing a stake of 50 shares — an estimated $1K sold.

Advisor Group first reported a position in KALV in Q2 2018 and held it in 4 quarters. The position peaked at $1K in Q1 2019. 75 funds tracked by Wall St. Rank hold KALV as of Q2 2019.

  • Advisor Group reported no remaining KalVista Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Advisor Group sold 50 KalVista Pharmaceuticals shares in Q2 2019, an estimated $1K.
  • Advisor Group first reported a position in KalVista Pharmaceuticals in Q2 2018 and held it in 4 quarters.
  • Advisor Group's KalVista Pharmaceuticals position peaked at $1K in Q1 2019.
  • 75 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2019.

Based on Advisor Group's 13F filing for Q2 2019, filed 31 Jul 2019.